...
首页> 外文期刊>Molecular BioSystems >Identification of novel selective MMP-9 inhibitors as potential anti-metastatic lead using structure-based hierarchical virtual screening and molecular dynamics simulation
【24h】

Identification of novel selective MMP-9 inhibitors as potential anti-metastatic lead using structure-based hierarchical virtual screening and molecular dynamics simulation

机译:基于结构的分层虚拟筛选和分子动力学模拟鉴定新型选择性MMP-9抑制剂作为潜在的抗转移铅

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

MMP-9 is an attractive target for the development of new anticancer drugs. In the current study, pharmacophore modeling was employed using two highly active and selective gelatinase inhibitors obtained from two X-ray crystal structures (PDB IDs: 2OVX and 2OW1) to identify novel selective MMP-9 inhibitors. The derived model was refined manually and also validated by the GH scoring method. The refined pharmacophore model, ADRR, was able to retrieve 86% of actives with a GH score of 0.774, indicating that the model was capable of retrieving the active MMP-9 inhibitors. ADRR was used to screen 2838166 unique structures. Hit filtration was carried out using a fitness score >1.5 and drug-likeness properties. Hierarchical clustering generates 33 clusters based on diversity. A total of 33 molecules were obtained and these molecules were taken for cross-docking studies with 5 subtype MMPs. Among 33 tested, 2 molecules, P10A-0000088030 (Lig-1) and P10A-0001383812 (Lig-2). were found to have the highest docking scores (-8.59 kcal mol~(-1) and -8.27 kcal mol~(-1)) towards MMP-9 compared with the other MMPs. Further MM-GBSA analysis was performed for two hits with 5 subtype MMPs to reveal the essential features that contribute to selectivity. The results showed that van der Waals contributions play a central role in determining the selectivity of MMP-9 inhibitors. Molecular dynamics studies were carried out for total time of 330 ns to assess the stability of ligands at the active site. MD analysis showed that binding of Lig-1 with MMP-9 is stable compared to that with Lig-2. Hence, we suggest the Lig-1 compound as a good lead in designing novel potent inhibitors of MMP-9.
机译:MMP-9是开发新型抗癌药物的诱人靶标。在当前的研究中,采用了从两种X射线晶体结构(PDB ID:2OVX和2OW1)获得的两种高活性和选择性明胶酶抑制剂进行药效团建模,以鉴定新型的选择性MMP-9抑制剂。手动精简得出的模型,并通过GH评分方法进行验证。改进的药效团模型ADRR能够检索86%的活性物,GH评分为0.774,表明该模型能够检索活性MMP-9抑制剂。 ADRR用于筛选2838166独特的结构。命中率过滤使用适应性评分> 1.5和药物相似性进行。分层聚类基于多样性生成33个聚类。共获得33个分子,并将这些分子与5个亚型MMP进行交叉对接研究。在测试的33个分子中,有2个分子是P10A-0000088030(Lig-1)和P10A-0001383812(Lig-2)。与其他MMP相比,MMP-9对MMP-9的对接得分最高(-8.59 kcal mol〜(-1)和-8.27 kcal mol〜(-1))。使用5个亚型MMP对两个命中进行了进一步的MM-GBSA分析,以揭示有助于选择性的基本特征。结果表明,范德华斯贡献在确定MMP-9抑制剂的选择性中起着核心作用。进行了分子动力学研究,总时间为330 ns,以评估活性位点上配体的稳定性。 MD分析显示与Mg-9相比,Lig-1与MMP-9的结合是稳定的。因此,我们建议将Lig-1化合物作为设计新型有效MMP-9抑制剂的良好先导。

著录项

  • 来源
    《Molecular BioSystems》 |2016年第8期|2519-2531|共13页
  • 作者单位

    Department of Pharmacy, University of Kwazulu Natal, Durban, South Africa;

    Department of Pharmacy, University of Kwazulu Natal, Durban, South Africa;

    Department of Pharmacy, University of Kwazulu Natal, Durban, South Africa;

    Department of Bioinformatics, School of Bioengineering, SRM University, Kancheepuram, Tamil nadu, India;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号